nodes	percent_of_prediction	percent_of_DWPC	metapath
Pseudoephedrine—IL2—blood vessel—systemic scleroderma	0.0271	0.201	CbGeAlD
Pseudoephedrine—NFATC1—connective tissue—systemic scleroderma	0.0152	0.113	CbGeAlD
Pseudoephedrine—IL2—connective tissue—systemic scleroderma	0.0139	0.103	CbGeAlD
Pseudoephedrine—IL2—skin of body—systemic scleroderma	0.0126	0.093	CbGeAlD
Pseudoephedrine—NFATC1—tendon—systemic scleroderma	0.0105	0.0774	CbGeAlD
Pseudoephedrine—IL2—digestive system—systemic scleroderma	0.01	0.0744	CbGeAlD
Pseudoephedrine—NFATC1—lung—systemic scleroderma	0.00917	0.0679	CbGeAlD
Pseudoephedrine—IL2—lung—systemic scleroderma	0.00839	0.0621	CbGeAlD
Pseudoephedrine—ADRB1—connective tissue—systemic scleroderma	0.00349	0.0258	CbGeAlD
Pseudoephedrine—MAOA—connective tissue—systemic scleroderma	0.00273	0.0202	CbGeAlD
Pseudoephedrine—Angina pectoris—Captopril—systemic scleroderma	0.00273	0.00743	CcSEcCtD
Pseudoephedrine—Arrhythmia—Pentoxifylline—systemic scleroderma	0.00264	0.00719	CcSEcCtD
Pseudoephedrine—Tension—Pentoxifylline—systemic scleroderma	0.00253	0.00688	CcSEcCtD
Pseudoephedrine—Nervousness—Pentoxifylline—systemic scleroderma	0.0025	0.00681	CcSEcCtD
Pseudoephedrine—Psychotic disorder—Mycophenolic acid—systemic scleroderma	0.00249	0.00677	CcSEcCtD
Pseudoephedrine—Muscle spasms—Pentoxifylline—systemic scleroderma	0.00247	0.00674	CcSEcCtD
Pseudoephedrine—SLC6A4—digestive system—systemic scleroderma	0.00243	0.018	CbGeAlD
Pseudoephedrine—Urinary retention—Mycophenolic acid—systemic scleroderma	0.00242	0.0066	CcSEcCtD
Pseudoephedrine—Tremor—Pentoxifylline—systemic scleroderma	0.00241	0.00657	CcSEcCtD
Pseudoephedrine—Agitation—Pentoxifylline—systemic scleroderma	0.00237	0.00644	CcSEcCtD
Pseudoephedrine—Palpitations—Pentoxifylline—systemic scleroderma	0.00227	0.0062	CcSEcCtD
Pseudoephedrine—Angina pectoris—Leflunomide—systemic scleroderma	0.00225	0.00612	CcSEcCtD
Pseudoephedrine—Hallucination—Captopril—systemic scleroderma	0.00223	0.00607	CcSEcCtD
Pseudoephedrine—Hypertension—Pentoxifylline—systemic scleroderma	0.00222	0.00605	CcSEcCtD
Pseudoephedrine—SLC6A3—lung—systemic scleroderma	0.00222	0.0164	CbGeAlD
Pseudoephedrine—Chest pain—Pentoxifylline—systemic scleroderma	0.00219	0.00597	CcSEcCtD
Pseudoephedrine—Irritability—Lisinopril—systemic scleroderma	0.00219	0.00596	CcSEcCtD
Pseudoephedrine—Anxiety—Pentoxifylline—systemic scleroderma	0.00218	0.00595	CcSEcCtD
Pseudoephedrine—Delirium—Prednisone—systemic scleroderma	0.00218	0.00594	CcSEcCtD
Pseudoephedrine—Dysuria—Leflunomide—systemic scleroderma	0.00216	0.00588	CcSEcCtD
Pseudoephedrine—Angina pectoris—Mycophenolic acid—systemic scleroderma	0.00214	0.00584	CcSEcCtD
Pseudoephedrine—Confusional state—Pentoxifylline—systemic scleroderma	0.00212	0.00577	CcSEcCtD
Pseudoephedrine—ADRB1—lung—systemic scleroderma	0.0021	0.0156	CbGeAlD
Pseudoephedrine—ADRA2A—connective tissue—systemic scleroderma	0.0021	0.0155	CbGeAlD
Pseudoephedrine—Dysuria—Mycophenolic acid—systemic scleroderma	0.00206	0.00561	CcSEcCtD
Pseudoephedrine—Tachycardia—Pentoxifylline—systemic scleroderma	0.00205	0.00558	CcSEcCtD
Pseudoephedrine—SLC6A4—lung—systemic scleroderma	0.00203	0.015	CbGeAlD
Pseudoephedrine—Hyperhidrosis—Pentoxifylline—systemic scleroderma	0.00203	0.00553	CcSEcCtD
Pseudoephedrine—Anorexia—Pentoxifylline—systemic scleroderma	0.002	0.00545	CcSEcCtD
Pseudoephedrine—MAOA—digestive system—systemic scleroderma	0.00197	0.0146	CbGeAlD
Pseudoephedrine—Psychotic disorder—Mycophenolate mofetil—systemic scleroderma	0.00196	0.00535	CcSEcCtD
Pseudoephedrine—Angina pectoris—Lisinopril—systemic scleroderma	0.00193	0.00526	CcSEcCtD
Pseudoephedrine—Tension—Captopril—systemic scleroderma	0.00191	0.00521	CcSEcCtD
Pseudoephedrine—Urinary retention—Mycophenolate mofetil—systemic scleroderma	0.00191	0.00521	CcSEcCtD
Pseudoephedrine—Insomnia—Pentoxifylline—systemic scleroderma	0.0019	0.00517	CcSEcCtD
Pseudoephedrine—Nervousness—Captopril—systemic scleroderma	0.00189	0.00516	CcSEcCtD
Pseudoephedrine—Chest pain—Mometasone—systemic scleroderma	0.00189	0.00515	CcSEcCtD
Pseudoephedrine—Sweating—Mycophenolic acid—systemic scleroderma	0.00188	0.00512	CcSEcCtD
Pseudoephedrine—MAOA—tendon—systemic scleroderma	0.00188	0.0139	CbGeAlD
Pseudoephedrine—Dyspnoea—Pentoxifylline—systemic scleroderma	0.00187	0.0051	CcSEcCtD
Pseudoephedrine—Dysuria—Lisinopril—systemic scleroderma	0.00185	0.00505	CcSEcCtD
Pseudoephedrine—Dyspepsia—Pentoxifylline—systemic scleroderma	0.00185	0.00504	CcSEcCtD
Pseudoephedrine—Decreased appetite—Pentoxifylline—systemic scleroderma	0.00183	0.00497	CcSEcCtD
Pseudoephedrine—Bradycardia—Mycophenolic acid—systemic scleroderma	0.00179	0.00488	CcSEcCtD
Pseudoephedrine—SLC6A2—lung—systemic scleroderma	0.00179	0.0132	CbGeAlD
Pseudoephedrine—Hallucination—Mycophenolic acid—systemic scleroderma	0.00175	0.00477	CcSEcCtD
Pseudoephedrine—Arrhythmia—Azathioprine—systemic scleroderma	0.00175	0.00476	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Pentoxifylline—systemic scleroderma	0.00173	0.00471	CcSEcCtD
Pseudoephedrine—Anorexia—Mometasone—systemic scleroderma	0.00173	0.00471	CcSEcCtD
Pseudoephedrine—Palpitations—Captopril—systemic scleroderma	0.00172	0.00469	CcSEcCtD
Pseudoephedrine—Sweating—Lisinopril—systemic scleroderma	0.00169	0.00462	CcSEcCtD
Pseudoephedrine—Angina pectoris—Mycophenolate mofetil—systemic scleroderma	0.00169	0.00461	CcSEcCtD
Pseudoephedrine—Chest pain—Captopril—systemic scleroderma	0.00166	0.00452	CcSEcCtD
Pseudoephedrine—Body temperature increased—Pentoxifylline—systemic scleroderma	0.00166	0.00452	CcSEcCtD
Pseudoephedrine—Arrhythmia—Leflunomide—systemic scleroderma	0.00165	0.00449	CcSEcCtD
Pseudoephedrine—MAOA—lung—systemic scleroderma	0.00165	0.0122	CbGeAlD
Pseudoephedrine—Dysuria—Mycophenolate mofetil—systemic scleroderma	0.00162	0.00442	CcSEcCtD
Pseudoephedrine—Dyspnoea—Mometasone—systemic scleroderma	0.00162	0.0044	CcSEcCtD
Pseudoephedrine—Bradycardia—Lisinopril—systemic scleroderma	0.00162	0.0044	CcSEcCtD
Pseudoephedrine—Euphoric mood—Prednisone—systemic scleroderma	0.00161	0.00439	CcSEcCtD
Pseudoephedrine—Confusional state—Captopril—systemic scleroderma	0.00161	0.00437	CcSEcCtD
Pseudoephedrine—Dyspepsia—Mometasone—systemic scleroderma	0.0016	0.00435	CcSEcCtD
Pseudoephedrine—Hallucination—Lisinopril—systemic scleroderma	0.00158	0.0043	CcSEcCtD
Pseudoephedrine—Decreased appetite—Mometasone—systemic scleroderma	0.00158	0.00429	CcSEcCtD
Pseudoephedrine—Arrhythmia—Mycophenolic acid—systemic scleroderma	0.00157	0.00429	CcSEcCtD
Pseudoephedrine—Tachycardia—Captopril—systemic scleroderma	0.00155	0.00423	CcSEcCtD
Pseudoephedrine—Pain—Mometasone—systemic scleroderma	0.00155	0.00422	CcSEcCtD
Pseudoephedrine—Muscle spasms—Leflunomide—systemic scleroderma	0.00155	0.00421	CcSEcCtD
Pseudoephedrine—Anorexia—Captopril—systemic scleroderma	0.00152	0.00413	CcSEcCtD
Pseudoephedrine—Asthenia—Pentoxifylline—systemic scleroderma	0.00151	0.0041	CcSEcCtD
Pseudoephedrine—Tension—Mycophenolic acid—systemic scleroderma	0.0015	0.0041	CcSEcCtD
Pseudoephedrine—Nervousness—Mycophenolic acid—systemic scleroderma	0.00149	0.00406	CcSEcCtD
Pseudoephedrine—Sweating—Mycophenolate mofetil—systemic scleroderma	0.00148	0.00404	CcSEcCtD
Pseudoephedrine—Muscle spasms—Mycophenolic acid—systemic scleroderma	0.00147	0.00402	CcSEcCtD
Pseudoephedrine—Vertigo—Leflunomide—systemic scleroderma	0.00144	0.00393	CcSEcCtD
Pseudoephedrine—ADRA2A—tendon—systemic scleroderma	0.00144	0.0107	CbGeAlD
Pseudoephedrine—Insomnia—Captopril—systemic scleroderma	0.00144	0.00392	CcSEcCtD
Pseudoephedrine—Tremor—Mycophenolic acid—systemic scleroderma	0.00144	0.00391	CcSEcCtD
Pseudoephedrine—Body temperature increased—Mometasone—systemic scleroderma	0.00143	0.0039	CcSEcCtD
Pseudoephedrine—Palpitations—Leflunomide—systemic scleroderma	0.00142	0.00387	CcSEcCtD
Pseudoephedrine—Dyspnoea—Captopril—systemic scleroderma	0.00142	0.00387	CcSEcCtD
Pseudoephedrine—Arrhythmia—Lisinopril—systemic scleroderma	0.00142	0.00386	CcSEcCtD
Pseudoephedrine—Bradycardia—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00386	CcSEcCtD
Pseudoephedrine—Agitation—Mycophenolic acid—systemic scleroderma	0.00141	0.00384	CcSEcCtD
Pseudoephedrine—Dyspepsia—Captopril—systemic scleroderma	0.0014	0.00382	CcSEcCtD
Pseudoephedrine—Dizziness—Pentoxifylline—systemic scleroderma	0.00139	0.00378	CcSEcCtD
Pseudoephedrine—Hypertension—Leflunomide—systemic scleroderma	0.00139	0.00378	CcSEcCtD
Pseudoephedrine—Decreased appetite—Captopril—systemic scleroderma	0.00138	0.00377	CcSEcCtD
Pseudoephedrine—Hallucination—Mycophenolate mofetil—systemic scleroderma	0.00138	0.00377	CcSEcCtD
Pseudoephedrine—Vertigo—Mycophenolic acid—systemic scleroderma	0.00138	0.00375	CcSEcCtD
Pseudoephedrine—Chest pain—Leflunomide—systemic scleroderma	0.00137	0.00373	CcSEcCtD
Pseudoephedrine—Anxiety—Leflunomide—systemic scleroderma	0.00136	0.00371	CcSEcCtD
Pseudoephedrine—Tension—Lisinopril—systemic scleroderma	0.00136	0.00369	CcSEcCtD
Pseudoephedrine—Palpitations—Mycophenolic acid—systemic scleroderma	0.00136	0.00369	CcSEcCtD
Pseudoephedrine—Nervousness—Lisinopril—systemic scleroderma	0.00134	0.00365	CcSEcCtD
Pseudoephedrine—Vomiting—Pentoxifylline—systemic scleroderma	0.00134	0.00364	CcSEcCtD
Pseudoephedrine—Psychotic disorder—Prednisone—systemic scleroderma	0.00133	0.00362	CcSEcCtD
Pseudoephedrine—Muscle spasms—Lisinopril—systemic scleroderma	0.00133	0.00362	CcSEcCtD
Pseudoephedrine—Rash—Pentoxifylline—systemic scleroderma	0.00132	0.00361	CcSEcCtD
Pseudoephedrine—Hypertension—Mycophenolic acid—systemic scleroderma	0.00132	0.00361	CcSEcCtD
Pseudoephedrine—Dermatitis—Pentoxifylline—systemic scleroderma	0.00132	0.0036	CcSEcCtD
Pseudoephedrine—Headache—Pentoxifylline—systemic scleroderma	0.00132	0.00358	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Captopril—systemic scleroderma	0.00131	0.00357	CcSEcCtD
Pseudoephedrine—Chest pain—Mycophenolic acid—systemic scleroderma	0.00131	0.00356	CcSEcCtD
Pseudoephedrine—Anxiety—Mycophenolic acid—systemic scleroderma	0.0013	0.00354	CcSEcCtD
Pseudoephedrine—Asthenia—Mometasone—systemic scleroderma	0.0013	0.00354	CcSEcCtD
Pseudoephedrine—Irritability—Prednisone—systemic scleroderma	0.0013	0.00354	CcSEcCtD
Pseudoephedrine—Tremor—Lisinopril—systemic scleroderma	0.00129	0.00353	CcSEcCtD
Pseudoephedrine—Tachycardia—Leflunomide—systemic scleroderma	0.00128	0.00349	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Leflunomide—systemic scleroderma	0.00127	0.00345	CcSEcCtD
Pseudoephedrine—ADRA2A—lung—systemic scleroderma	0.00126	0.00936	CbGeAlD
Pseudoephedrine—Confusional state—Mycophenolic acid—systemic scleroderma	0.00126	0.00344	CcSEcCtD
Pseudoephedrine—Body temperature increased—Captopril—systemic scleroderma	0.00126	0.00343	CcSEcCtD
Pseudoephedrine—Anorexia—Leflunomide—systemic scleroderma	0.00125	0.00341	CcSEcCtD
Pseudoephedrine—Nausea—Pentoxifylline—systemic scleroderma	0.00125	0.0034	CcSEcCtD
Pseudoephedrine—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.00124	0.00338	CcSEcCtD
Pseudoephedrine—Vertigo—Lisinopril—systemic scleroderma	0.00124	0.00338	CcSEcCtD
Pseudoephedrine—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00122	0.00333	CcSEcCtD
Pseudoephedrine—Palpitations—Lisinopril—systemic scleroderma	0.00122	0.00332	CcSEcCtD
Pseudoephedrine—NFATC1—Ectoderm Differentiation—CCL2—systemic scleroderma	0.00121	0.00244	CbGpPWpGaD
Pseudoephedrine—TNF—TNF alpha Signaling Pathway—TNFAIP3—systemic scleroderma	0.00121	0.00244	CbGpPWpGaD
Pseudoephedrine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00121	0.0033	CcSEcCtD
Pseudoephedrine—ADRA1A—Endothelin Pathways—EDN1—systemic scleroderma	0.0012	0.0024	CbGpPWpGaD
Pseudoephedrine—Anorexia—Mycophenolic acid—systemic scleroderma	0.00119	0.00325	CcSEcCtD
Pseudoephedrine—Tension—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00323	CcSEcCtD
Pseudoephedrine—Insomnia—Leflunomide—systemic scleroderma	0.00119	0.00323	CcSEcCtD
Pseudoephedrine—Chest pain—Lisinopril—systemic scleroderma	0.00118	0.0032	CcSEcCtD
Pseudoephedrine—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.00118	0.0032	CcSEcCtD
Pseudoephedrine—CYP2D6—digestive system—systemic scleroderma	0.00117	0.00868	CbGeAlD
Pseudoephedrine—Anxiety—Lisinopril—systemic scleroderma	0.00117	0.00319	CcSEcCtD
Pseudoephedrine—Dyspnoea—Leflunomide—systemic scleroderma	0.00117	0.00319	CcSEcCtD
Pseudoephedrine—TNF—amb2 Integrin signaling—MMP2—systemic scleroderma	0.00117	0.00235	CbGpPWpGaD
Pseudoephedrine—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00116	0.00317	CcSEcCtD
Pseudoephedrine—IL2—Spinal Cord Injury—CCL2—systemic scleroderma	0.00116	0.00234	CbGpPWpGaD
Pseudoephedrine—Dyspepsia—Leflunomide—systemic scleroderma	0.00115	0.00315	CcSEcCtD
Pseudoephedrine—Vomiting—Mometasone—systemic scleroderma	0.00115	0.00314	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Azathioprine—systemic scleroderma	0.00114	0.00312	CcSEcCtD
Pseudoephedrine—Rash—Mometasone—systemic scleroderma	0.00114	0.00311	CcSEcCtD
Pseudoephedrine—Asthenia—Captopril—systemic scleroderma	0.00114	0.00311	CcSEcCtD
Pseudoephedrine—Dermatitis—Mometasone—systemic scleroderma	0.00114	0.00311	CcSEcCtD
Pseudoephedrine—Decreased appetite—Leflunomide—systemic scleroderma	0.00114	0.00311	CcSEcCtD
Pseudoephedrine—Confusional state—Lisinopril—systemic scleroderma	0.00114	0.0031	CcSEcCtD
Pseudoephedrine—Headache—Mometasone—systemic scleroderma	0.00114	0.00309	CcSEcCtD
Pseudoephedrine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00113	0.00309	CcSEcCtD
Pseudoephedrine—Insomnia—Mycophenolic acid—systemic scleroderma	0.00113	0.00308	CcSEcCtD
Pseudoephedrine—Pain—Leflunomide—systemic scleroderma	0.00112	0.00306	CcSEcCtD
Pseudoephedrine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00112	0.00304	CcSEcCtD
Pseudoephedrine—IL2—Hemostasis—SELP—systemic scleroderma	0.00111	0.00224	CbGpPWpGaD
Pseudoephedrine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00111	0.00303	CcSEcCtD
Pseudoephedrine—TNF—Allograft Rejection—CTLA4—systemic scleroderma	0.00111	0.00223	CbGpPWpGaD
Pseudoephedrine—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.0011	0.003	CcSEcCtD
Pseudoephedrine—Tachycardia—Lisinopril—systemic scleroderma	0.0011	0.003	CcSEcCtD
Pseudoephedrine—TNF—IL27-mediated signaling events—IL1B—systemic scleroderma	0.0011	0.00221	CbGpPWpGaD
Pseudoephedrine—Body temperature increased—Azathioprine—systemic scleroderma	0.0011	0.00299	CcSEcCtD
Pseudoephedrine—TNF—IL23-mediated signaling events—CCL2—systemic scleroderma	0.00109	0.0022	CbGpPWpGaD
Pseudoephedrine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00109	0.00297	CcSEcCtD
Pseudoephedrine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00109	0.00296	CcSEcCtD
Pseudoephedrine—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00109	0.00296	CcSEcCtD
Pseudoephedrine—Irritability—Methotrexate—systemic scleroderma	0.00109	0.00296	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Leflunomide—systemic scleroderma	0.00108	0.00294	CcSEcCtD
Pseudoephedrine—SLC6A4—Monoamine Transport—IL1B—systemic scleroderma	0.00108	0.00217	CbGpPWpGaD
Pseudoephedrine—Nausea—Mometasone—systemic scleroderma	0.00108	0.00293	CcSEcCtD
Pseudoephedrine—Anorexia—Lisinopril—systemic scleroderma	0.00107	0.00293	CcSEcCtD
Pseudoephedrine—Pain—Mycophenolic acid—systemic scleroderma	0.00107	0.00292	CcSEcCtD
Pseudoephedrine—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00107	0.00291	CcSEcCtD
Pseudoephedrine—TNF—Cytokines and Inflammatory Response—IL1B—systemic scleroderma	0.00107	0.00214	CbGpPWpGaD
Pseudoephedrine—IL2—Regulation of Telomerase—TGFB1—systemic scleroderma	0.00106	0.00214	CbGpPWpGaD
Pseudoephedrine—Dizziness—Captopril—systemic scleroderma	0.00105	0.00287	CcSEcCtD
Pseudoephedrine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00285	CcSEcCtD
Pseudoephedrine—IL2—AP-1 transcription factor network—TGFB1—systemic scleroderma	0.00104	0.00209	CbGpPWpGaD
Pseudoephedrine—IL2—Hemostasis—RHOB—systemic scleroderma	0.00104	0.00209	CbGpPWpGaD
Pseudoephedrine—Body temperature increased—Leflunomide—systemic scleroderma	0.00104	0.00282	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00103	0.00281	CcSEcCtD
Pseudoephedrine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00281	CcSEcCtD
Pseudoephedrine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.00103	0.0028	CcSEcCtD
Pseudoephedrine—Insomnia—Lisinopril—systemic scleroderma	0.00102	0.00278	CcSEcCtD
Pseudoephedrine—Vomiting—Captopril—systemic scleroderma	0.00101	0.00276	CcSEcCtD
Pseudoephedrine—NFATC1—TCR Signaling Pathway—TGFB1—systemic scleroderma	0.00101	0.00202	CbGpPWpGaD
Pseudoephedrine—Dyspnoea—Lisinopril—systemic scleroderma	0.00101	0.00274	CcSEcCtD
Pseudoephedrine—Rash—Captopril—systemic scleroderma	0.001	0.00273	CcSEcCtD
Pseudoephedrine—Dermatitis—Captopril—systemic scleroderma	0.001	0.00273	CcSEcCtD
Pseudoephedrine—Headache—Captopril—systemic scleroderma	0.000997	0.00272	CcSEcCtD
Pseudoephedrine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000996	0.00271	CcSEcCtD
Pseudoephedrine—Dyspepsia—Lisinopril—systemic scleroderma	0.000992	0.0027	CcSEcCtD
Pseudoephedrine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000989	0.00269	CcSEcCtD
Pseudoephedrine—TNF—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.000988	0.00199	CbGpPWpGaD
Pseudoephedrine—Decreased appetite—Lisinopril—systemic scleroderma	0.00098	0.00267	CcSEcCtD
Pseudoephedrine—TNF—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.000974	0.00196	CbGpPWpGaD
Pseudoephedrine—Pain—Lisinopril—systemic scleroderma	0.000964	0.00263	CcSEcCtD
Pseudoephedrine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000964	0.00263	CcSEcCtD
Pseudoephedrine—Bradycardia—Prednisone—systemic scleroderma	0.000959	0.00261	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000955	0.0026	CcSEcCtD
Pseudoephedrine—NFATC1—Innate Immune System—ITGAM—systemic scleroderma	0.000947	0.0019	CbGpPWpGaD
Pseudoephedrine—NFATC1—Innate Immune System—CD247—systemic scleroderma	0.000947	0.0019	CbGpPWpGaD
Pseudoephedrine—IL2—Hemostasis—CSK—systemic scleroderma	0.000946	0.0019	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by Interleukins—IL1B—systemic scleroderma	0.000946	0.0019	CbGpPWpGaD
Pseudoephedrine—Nausea—Captopril—systemic scleroderma	0.000946	0.00258	CcSEcCtD
Pseudoephedrine—IL2—Allograft Rejection—TGFB1—systemic scleroderma	0.000944	0.0019	CbGpPWpGaD
Pseudoephedrine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000942	0.00256	CcSEcCtD
Pseudoephedrine—Asthenia—Leflunomide—systemic scleroderma	0.000941	0.00256	CcSEcCtD
Pseudoephedrine—Hallucination—Prednisone—systemic scleroderma	0.000938	0.00255	CcSEcCtD
Pseudoephedrine—TNF—Monoamine Transport—IL1B—systemic scleroderma	0.000932	0.00187	CbGpPWpGaD
Pseudoephedrine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000929	0.00253	CcSEcCtD
Pseudoephedrine—SLC6A2—Monoamine Transport—IL1B—systemic scleroderma	0.000928	0.00186	CbGpPWpGaD
Pseudoephedrine—SLC6A4—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000926	0.00186	CbGpPWpGaD
Pseudoephedrine—TNF—Matrix Metalloproteinases—MMP9—systemic scleroderma	0.000925	0.00186	CbGpPWpGaD
Pseudoephedrine—Dysuria—Methotrexate—systemic scleroderma	0.00092	0.00251	CcSEcCtD
Pseudoephedrine—Dizziness—Azathioprine—systemic scleroderma	0.000919	0.0025	CcSEcCtD
Pseudoephedrine—TNF—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000913	0.00183	CbGpPWpGaD
Pseudoephedrine—ADRB1—Endothelin Pathways—NOS3—systemic scleroderma	0.000901	0.00181	CbGpPWpGaD
Pseudoephedrine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000898	0.00245	CcSEcCtD
Pseudoephedrine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000893	0.00243	CcSEcCtD
Pseudoephedrine—IL2—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.000892	0.00179	CbGpPWpGaD
Pseudoephedrine—Body temperature increased—Lisinopril—systemic scleroderma	0.000891	0.00243	CcSEcCtD
Pseudoephedrine—IL2—Hemostasis—ITGAM—systemic scleroderma	0.00089	0.00179	CbGpPWpGaD
Pseudoephedrine—NFATC1—Innate Immune System—TNFAIP3—systemic scleroderma	0.000887	0.00178	CbGpPWpGaD
Pseudoephedrine—Vomiting—Azathioprine—systemic scleroderma	0.000883	0.00241	CcSEcCtD
Pseudoephedrine—IL2—Spinal Cord Injury—IL1B—systemic scleroderma	0.000882	0.00177	CbGpPWpGaD
Pseudoephedrine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000881	0.0024	CcSEcCtD
Pseudoephedrine—TNF—amb2 Integrin signaling—MMP9—systemic scleroderma	0.000878	0.00176	CbGpPWpGaD
Pseudoephedrine—Rash—Azathioprine—systemic scleroderma	0.000876	0.00239	CcSEcCtD
Pseudoephedrine—Dermatitis—Azathioprine—systemic scleroderma	0.000875	0.00238	CcSEcCtD
Pseudoephedrine—TNF—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.000872	0.00175	CbGpPWpGaD
Pseudoephedrine—Headache—Azathioprine—systemic scleroderma	0.00087	0.00237	CcSEcCtD
Pseudoephedrine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000869	0.00237	CcSEcCtD
Pseudoephedrine—Dizziness—Leflunomide—systemic scleroderma	0.000868	0.00236	CcSEcCtD
Pseudoephedrine—TNF—Allograft Rejection—IL1A—systemic scleroderma	0.000867	0.00174	CbGpPWpGaD
Pseudoephedrine—TNF—Allograft Rejection—CD40LG—systemic scleroderma	0.000862	0.00173	CbGpPWpGaD
Pseudoephedrine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000859	0.00234	CcSEcCtD
Pseudoephedrine—TNF—IL27-mediated signaling events—TGFB1—systemic scleroderma	0.000855	0.00172	CbGpPWpGaD
Pseudoephedrine—TNF—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—systemic scleroderma	0.000855	0.00172	CbGpPWpGaD
Pseudoephedrine—IL2—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	0.000847	0.0017	CbGpPWpGaD
Pseudoephedrine—TNF—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.000846	0.0017	CbGpPWpGaD
Pseudoephedrine—Pain—Mycophenolate mofetil—systemic scleroderma	0.000845	0.0023	CcSEcCtD
Pseudoephedrine—Arrhythmia—Prednisone—systemic scleroderma	0.000842	0.00229	CcSEcCtD
Pseudoephedrine—Sweating—Methotrexate—systemic scleroderma	0.000841	0.00229	CcSEcCtD
Pseudoephedrine—IL2—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	0.000836	0.00168	CbGpPWpGaD
Pseudoephedrine—Vomiting—Leflunomide—systemic scleroderma	0.000834	0.00227	CcSEcCtD
Pseudoephedrine—IL2—Spinal Cord Injury—MMP9—systemic scleroderma	0.000831	0.00167	CbGpPWpGaD
Pseudoephedrine—TNF—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.00083	0.00167	CbGpPWpGaD
Pseudoephedrine—TNF—IL23-mediated signaling events—IL1B—systemic scleroderma	0.00083	0.00167	CbGpPWpGaD
Pseudoephedrine—TNF—Cytokines and Inflammatory Response—TGFB1—systemic scleroderma	0.000829	0.00167	CbGpPWpGaD
Pseudoephedrine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000828	0.00225	CcSEcCtD
Pseudoephedrine—Rash—Leflunomide—systemic scleroderma	0.000827	0.00225	CcSEcCtD
Pseudoephedrine—Dermatitis—Leflunomide—systemic scleroderma	0.000826	0.00225	CcSEcCtD
Pseudoephedrine—Nausea—Azathioprine—systemic scleroderma	0.000825	0.00225	CcSEcCtD
Pseudoephedrine—Headache—Leflunomide—systemic scleroderma	0.000822	0.00224	CcSEcCtD
Pseudoephedrine—SLC6A3—Monoamine Transport—IL1B—systemic scleroderma	0.000822	0.00165	CbGpPWpGaD
Pseudoephedrine—TNF—Angiopoietin receptor Tie2-mediated signaling—MMP2—systemic scleroderma	0.000818	0.00164	CbGpPWpGaD
Pseudoephedrine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000814	0.00222	CcSEcCtD
Pseudoephedrine—Asthenia—Lisinopril—systemic scleroderma	0.000809	0.0022	CcSEcCtD
Pseudoephedrine—CYP2D6—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000803	0.00161	CbGpPWpGaD
Pseudoephedrine—TNF—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.0008	0.00161	CbGpPWpGaD
Pseudoephedrine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000796	0.00217	CcSEcCtD
Pseudoephedrine—Rash—Mycophenolic acid—systemic scleroderma	0.000789	0.00215	CcSEcCtD
Pseudoephedrine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000788	0.00215	CcSEcCtD
Pseudoephedrine—NFATC1—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000786	0.00158	CbGpPWpGaD
Pseudoephedrine—Headache—Mycophenolic acid—systemic scleroderma	0.000784	0.00214	CcSEcCtD
Pseudoephedrine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000781	0.00213	CcSEcCtD
Pseudoephedrine—Nausea—Leflunomide—systemic scleroderma	0.000779	0.00212	CcSEcCtD
Pseudoephedrine—NFATC1—Disease—SMAD7—systemic scleroderma	0.000769	0.00154	CbGpPWpGaD
Pseudoephedrine—TNF—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic scleroderma	0.000766	0.00154	CbGpPWpGaD
Pseudoephedrine—MAOA—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000759	0.00152	CbGpPWpGaD
Pseudoephedrine—Agitation—Prednisone—systemic scleroderma	0.000754	0.00205	CcSEcCtD
Pseudoephedrine—Dizziness—Lisinopril—systemic scleroderma	0.000745	0.00203	CcSEcCtD
Pseudoephedrine—Nausea—Mycophenolic acid—systemic scleroderma	0.000743	0.00202	CcSEcCtD
Pseudoephedrine—Vertigo—Prednisone—systemic scleroderma	0.000737	0.00201	CcSEcCtD
Pseudoephedrine—ADRA1A—Endothelin Pathways—NOS3—systemic scleroderma	0.000729	0.00146	CbGpPWpGaD
Pseudoephedrine—Vomiting—Lisinopril—systemic scleroderma	0.000717	0.00195	CcSEcCtD
Pseudoephedrine—Rash—Lisinopril—systemic scleroderma	0.000711	0.00194	CcSEcCtD
Pseudoephedrine—Dermatitis—Lisinopril—systemic scleroderma	0.00071	0.00193	CcSEcCtD
Pseudoephedrine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000709	0.00193	CcSEcCtD
Pseudoephedrine—Hypertension—Prednisone—systemic scleroderma	0.000708	0.00193	CcSEcCtD
Pseudoephedrine—TNF—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.000707	0.00142	CbGpPWpGaD
Pseudoephedrine—Headache—Lisinopril—systemic scleroderma	0.000706	0.00192	CcSEcCtD
Pseudoephedrine—NFATC1—Disease—TGFBI—systemic scleroderma	0.000703	0.00141	CbGpPWpGaD
Pseudoephedrine—TNF—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000697	0.0014	CbGpPWpGaD
Pseudoephedrine—Anxiety—Prednisone—systemic scleroderma	0.000696	0.0019	CcSEcCtD
Pseudoephedrine—TNF—Folate Metabolism—CCL2—systemic scleroderma	0.000688	0.00138	CbGpPWpGaD
Pseudoephedrine—IL2—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000685	0.00138	CbGpPWpGaD
Pseudoephedrine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—systemic scleroderma	0.000672	0.00135	CbGpPWpGaD
Pseudoephedrine—Nausea—Lisinopril—systemic scleroderma	0.00067	0.00182	CcSEcCtD
Pseudoephedrine—IL2—GPCR downstream signaling—RHOB—systemic scleroderma	0.000657	0.00132	CbGpPWpGaD
Pseudoephedrine—Tachycardia—Prednisone—systemic scleroderma	0.000653	0.00178	CcSEcCtD
Pseudoephedrine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000653	0.00178	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000647	0.00176	CcSEcCtD
Pseudoephedrine—TNF—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.000642	0.00129	CbGpPWpGaD
Pseudoephedrine—Anorexia—Prednisone—systemic scleroderma	0.000638	0.00174	CcSEcCtD
Pseudoephedrine—TNF—Spinal Cord Injury—IL1A—systemic scleroderma	0.000629	0.00126	CbGpPWpGaD
Pseudoephedrine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000628	0.00171	CcSEcCtD
Pseudoephedrine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000623	0.0017	CcSEcCtD
Pseudoephedrine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000622	0.00169	CcSEcCtD
Pseudoephedrine—Headache—Mycophenolate mofetil—systemic scleroderma	0.000619	0.00169	CcSEcCtD
Pseudoephedrine—Vertigo—Methotrexate—systemic scleroderma	0.000616	0.00168	CcSEcCtD
Pseudoephedrine—NFATC1—MAPK Signaling Pathway—TGFB1—systemic scleroderma	0.000611	0.00123	CbGpPWpGaD
Pseudoephedrine—Insomnia—Prednisone—systemic scleroderma	0.000606	0.00165	CcSEcCtD
Pseudoephedrine—IL2—Signaling by GPCR—RHOB—systemic scleroderma	0.000596	0.0012	CbGpPWpGaD
Pseudoephedrine—Dyspepsia—Prednisone—systemic scleroderma	0.000589	0.00161	CcSEcCtD
Pseudoephedrine—NFATC1—Immune System—CSK—systemic scleroderma	0.000587	0.00118	CbGpPWpGaD
Pseudoephedrine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000587	0.0016	CcSEcCtD
Pseudoephedrine—Chest pain—Methotrexate—systemic scleroderma	0.000584	0.00159	CcSEcCtD
Pseudoephedrine—SLC6A4—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000582	0.00117	CbGpPWpGaD
Pseudoephedrine—Decreased appetite—Prednisone—systemic scleroderma	0.000582	0.00159	CcSEcCtD
Pseudoephedrine—NFATC1—Immune System—IRF5—systemic scleroderma	0.000577	0.00116	CbGpPWpGaD
Pseudoephedrine—Confusional state—Methotrexate—systemic scleroderma	0.000564	0.00154	CcSEcCtD
Pseudoephedrine—NFATC1—Disease—HSPG2—systemic scleroderma	0.000561	0.00113	CbGpPWpGaD
Pseudoephedrine—Feeling abnormal—Prednisone—systemic scleroderma	0.000552	0.0015	CcSEcCtD
Pseudoephedrine—NFATC1—Immune System—IRF8—systemic scleroderma	0.000552	0.00111	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—ITGAM—systemic scleroderma	0.000552	0.00111	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—CD247—systemic scleroderma	0.000552	0.00111	CbGpPWpGaD
Pseudoephedrine—TNF—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000547	0.0011	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—CSK—systemic scleroderma	0.000542	0.00109	CbGpPWpGaD
Pseudoephedrine—TNF—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000542	0.00109	CbGpPWpGaD
Pseudoephedrine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000541	0.00147	CcSEcCtD
Pseudoephedrine—NFATC1—Signaling Pathways—SMAD7—systemic scleroderma	0.000538	0.00108	CbGpPWpGaD
Pseudoephedrine—Anorexia—Methotrexate—systemic scleroderma	0.000533	0.00145	CcSEcCtD
Pseudoephedrine—Body temperature increased—Prednisone—systemic scleroderma	0.000529	0.00144	CcSEcCtD
Pseudoephedrine—TNF—TNF alpha Signaling Pathway—CCL2—systemic scleroderma	0.000528	0.00106	CbGpPWpGaD
Pseudoephedrine—TNF—Folate Metabolism—IL1B—systemic scleroderma	0.000522	0.00105	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—TNFAIP3—systemic scleroderma	0.000517	0.00104	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—BLK—systemic scleroderma	0.00051	0.00103	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000509	0.00102	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—CD247—systemic scleroderma	0.000509	0.00102	CbGpPWpGaD
Pseudoephedrine—Insomnia—Methotrexate—systemic scleroderma	0.000506	0.00138	CcSEcCtD
Pseudoephedrine—TNF—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000503	0.00101	CbGpPWpGaD
Pseudoephedrine—Dyspnoea—Methotrexate—systemic scleroderma	0.000499	0.00136	CcSEcCtD
Pseudoephedrine—IL2—Immune System—CSK—systemic scleroderma	0.000496	0.000997	CbGpPWpGaD
Pseudoephedrine—Dyspepsia—Methotrexate—systemic scleroderma	0.000493	0.00134	CcSEcCtD
Pseudoephedrine—IL2—Immune System—IRF5—systemic scleroderma	0.000488	0.000981	CbGpPWpGaD
Pseudoephedrine—Decreased appetite—Methotrexate—systemic scleroderma	0.000486	0.00132	CcSEcCtD
Pseudoephedrine—Asthenia—Prednisone—systemic scleroderma	0.00048	0.00131	CcSEcCtD
Pseudoephedrine—Pain—Methotrexate—systemic scleroderma	0.000478	0.0013	CcSEcCtD
Pseudoephedrine—MAOA—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000477	0.000959	CbGpPWpGaD
Pseudoephedrine—TNF—TGF-beta Receptor Signaling—TGFB1—systemic scleroderma	0.000476	0.000957	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000476	0.000955	CbGpPWpGaD
Pseudoephedrine—TNF—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000474	0.000953	CbGpPWpGaD
Pseudoephedrine—TNF—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000469	0.000943	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—CD247—systemic scleroderma	0.000467	0.000937	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—IRF8—systemic scleroderma	0.000467	0.000937	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—ITGAM—systemic scleroderma	0.000467	0.000937	CbGpPWpGaD
Pseudoephedrine—Feeling abnormal—Methotrexate—systemic scleroderma	0.000461	0.00126	CcSEcCtD
Pseudoephedrine—IL2—Signaling Pathways—SMAD7—systemic scleroderma	0.000455	0.000915	CbGpPWpGaD
Pseudoephedrine—TNF—Allograft Rejection—IL1B—systemic scleroderma	0.000452	0.000908	CbGpPWpGaD
Pseudoephedrine—TNF—Alzheimers Disease—IL1B—systemic scleroderma	0.000452	0.000908	CbGpPWpGaD
Pseudoephedrine—IL2—Hemostasis—MMP1—systemic scleroderma	0.000446	0.000896	CbGpPWpGaD
Pseudoephedrine—Dizziness—Prednisone—systemic scleroderma	0.000443	0.00121	CcSEcCtD
Pseudoephedrine—Body temperature increased—Methotrexate—systemic scleroderma	0.000442	0.0012	CcSEcCtD
Pseudoephedrine—IL2—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	0.000442	0.000887	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—TNFAIP3—systemic scleroderma	0.000437	0.000878	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000433	0.00087	CbGpPWpGaD
Pseudoephedrine—TNF—Spinal Cord Injury—CCL2—systemic scleroderma	0.000432	0.000869	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—BLK—systemic scleroderma	0.000432	0.000867	CbGpPWpGaD
Pseudoephedrine—Vomiting—Prednisone—systemic scleroderma	0.000426	0.00116	CcSEcCtD
Pseudoephedrine—Rash—Prednisone—systemic scleroderma	0.000422	0.00115	CcSEcCtD
Pseudoephedrine—Dermatitis—Prednisone—systemic scleroderma	0.000422	0.00115	CcSEcCtD
Pseudoephedrine—Headache—Prednisone—systemic scleroderma	0.000419	0.00114	CcSEcCtD
Pseudoephedrine—NFATC1—Immune System—CTLA4—systemic scleroderma	0.000418	0.00084	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—RHOB—systemic scleroderma	0.000417	0.000837	CbGpPWpGaD
Pseudoephedrine—TNF—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000415	0.000833	CbGpPWpGaD
Pseudoephedrine—IL2—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	0.000415	0.000833	CbGpPWpGaD
Pseudoephedrine—Asthenia—Methotrexate—systemic scleroderma	0.000401	0.00109	CcSEcCtD
Pseudoephedrine—Nausea—Prednisone—systemic scleroderma	0.000398	0.00108	CcSEcCtD
Pseudoephedrine—TNF—Developmental Biology—RHOB—systemic scleroderma	0.000394	0.000792	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—HSPG2—systemic scleroderma	0.000393	0.000789	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—CSK—systemic scleroderma	0.000379	0.000762	CbGpPWpGaD
Pseudoephedrine—Dizziness—Methotrexate—systemic scleroderma	0.00037	0.00101	CcSEcCtD
Pseudoephedrine—TNF—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.000369	0.00074	CbGpPWpGaD
Pseudoephedrine—TNF—Transcriptional regulation of white adipocyte differentiation—TGFB1—systemic scleroderma	0.000359	0.000721	CbGpPWpGaD
Pseudoephedrine—Vomiting—Methotrexate—systemic scleroderma	0.000356	0.000969	CcSEcCtD
Pseudoephedrine—IL2—Immune System—CTLA4—systemic scleroderma	0.000354	0.00071	CbGpPWpGaD
Pseudoephedrine—Rash—Methotrexate—systemic scleroderma	0.000353	0.000961	CcSEcCtD
Pseudoephedrine—Dermatitis—Methotrexate—systemic scleroderma	0.000352	0.00096	CcSEcCtD
Pseudoephedrine—IL2—Signaling Pathways—RHOB—systemic scleroderma	0.000352	0.000708	CbGpPWpGaD
Pseudoephedrine—TNF—Allograft Rejection—TGFB1—systemic scleroderma	0.000351	0.000706	CbGpPWpGaD
Pseudoephedrine—Headache—Methotrexate—systemic scleroderma	0.000351	0.000955	CcSEcCtD
Pseudoephedrine—NFATC1—Immune System—HLA-DQB1—systemic scleroderma	0.000344	0.000692	CbGpPWpGaD
Pseudoephedrine—IL2—GPCR downstream signaling—EDN1—systemic scleroderma	0.000335	0.000674	CbGpPWpGaD
Pseudoephedrine—TNF—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000335	0.000672	CbGpPWpGaD
Pseudoephedrine—Nausea—Methotrexate—systemic scleroderma	0.000332	0.000905	CcSEcCtD
Pseudoephedrine—IL2—Signaling Pathways—HSPG2—systemic scleroderma	0.000332	0.000667	CbGpPWpGaD
Pseudoephedrine—TNF—Spinal Cord Injury—IL1B—systemic scleroderma	0.000328	0.000659	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—IL1A—systemic scleroderma	0.000327	0.000657	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—CD40LG—systemic scleroderma	0.000325	0.000653	CbGpPWpGaD
Pseudoephedrine—IL2—Hemostasis—NOS3—systemic scleroderma	0.000323	0.000649	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—CSK—systemic scleroderma	0.000321	0.000645	CbGpPWpGaD
Pseudoephedrine—TNF—Spinal Cord Injury—MMP9—systemic scleroderma	0.000309	0.000621	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by GPCR—EDN1—systemic scleroderma	0.000304	0.000612	CbGpPWpGaD
Pseudoephedrine—SLC6A4—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000304	0.00061	CbGpPWpGaD
Pseudoephedrine—ADRA1A—G alpha (q) signalling events—EDN1—systemic scleroderma	0.000299	0.0006	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—HLA-DQB1—systemic scleroderma	0.000291	0.000585	CbGpPWpGaD
Pseudoephedrine—TNF—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000288	0.000578	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—IL1A—systemic scleroderma	0.000277	0.000556	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—CD40LG—systemic scleroderma	0.000275	0.000552	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000267	0.000537	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—SELP—systemic scleroderma	0.000263	0.000527	CbGpPWpGaD
Pseudoephedrine—TNF—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000262	0.000527	CbGpPWpGaD
Pseudoephedrine—TNF—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000255	0.000512	CbGpPWpGaD
Pseudoephedrine—MAOA—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000249	0.0005	CbGpPWpGaD
Pseudoephedrine—SLC6A4—NRF2 pathway—TGFB1—systemic scleroderma	0.000249	0.0005	CbGpPWpGaD
Pseudoephedrine—TNF—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000247	0.000497	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—RHOB—systemic scleroderma	0.000245	0.000492	CbGpPWpGaD
Pseudoephedrine—ADRB1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000244	0.000491	CbGpPWpGaD
Pseudoephedrine—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000239	0.00048	CbGpPWpGaD
Pseudoephedrine—TNF—Adipogenesis—TGFB1—systemic scleroderma	0.000236	0.000474	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—CSK—systemic scleroderma	0.000223	0.000449	CbGpPWpGaD
Pseudoephedrine—SLC6A2—NRF2 pathway—TGFB1—systemic scleroderma	0.000214	0.00043	CbGpPWpGaD
Pseudoephedrine—IL2—Hemostasis—TGFB1—systemic scleroderma	0.000214	0.000429	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—EDN1—systemic scleroderma	0.000213	0.000427	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—ITGAM—systemic scleroderma	0.00021	0.000422	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by GPCR—CCL2—systemic scleroderma	0.000208	0.000418	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—RHOB—systemic scleroderma	0.000206	0.000414	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—RHOB—systemic scleroderma	0.000202	0.000405	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000198	0.000397	CbGpPWpGaD
Pseudoephedrine—TNF—MAPK Signaling Pathway—TGFB1—systemic scleroderma	0.000192	0.000386	CbGpPWpGaD
Pseudoephedrine—SLC6A3—NRF2 pathway—TGFB1—systemic scleroderma	0.00019	0.000381	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—RHOB—systemic scleroderma	0.000187	0.000376	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR ligand binding—EDN1—systemic scleroderma	0.000186	0.000374	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—NOS3—systemic scleroderma	0.000185	0.000372	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000184	0.000369	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—RHOB—systemic scleroderma	0.000183	0.000368	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR ligand binding—EDN1—systemic scleroderma	0.000182	0.000366	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—EDN1—systemic scleroderma	0.00018	0.000361	CbGpPWpGaD
Pseudoephedrine—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000173	0.000348	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—IL1B—systemic scleroderma	0.000171	0.000343	CbGpPWpGaD
Pseudoephedrine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000167	0.000336	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—RHOB—systemic scleroderma	0.000167	0.000335	CbGpPWpGaD
Pseudoephedrine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000163	0.000328	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—RHOB—systemic scleroderma	0.000155	0.000311	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—RHOB—systemic scleroderma	0.000151	0.000304	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR ligand binding—EDN1—systemic scleroderma	0.000151	0.000303	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—CCL2—systemic scleroderma	0.000145	0.000292	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—IL1B—systemic scleroderma	0.000144	0.00029	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—SMAD7—systemic scleroderma	0.000143	0.000287	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—RHOB—systemic scleroderma	0.000141	0.000283	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—HSPG2—systemic scleroderma	0.00014	0.000282	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR ligand binding—EDN1—systemic scleroderma	0.00014	0.000281	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—SMAD7—systemic scleroderma	0.00014	0.000281	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000135	0.000272	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—MMP2—systemic scleroderma	0.000131	0.000263	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—NOS3—systemic scleroderma	0.00013	0.00026	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR ligand binding—CCL2—systemic scleroderma	0.000127	0.000256	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000126	0.000252	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR ligand binding—CCL2—systemic scleroderma	0.000124	0.00025	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—CCL2—systemic scleroderma	0.000123	0.000247	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—TGFB1—systemic scleroderma	0.000122	0.000246	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—SMAD7—systemic scleroderma	0.000116	0.000232	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—RHOB—systemic scleroderma	0.000111	0.000222	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—NOS3—systemic scleroderma	0.00011	0.00022	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—RHOB—systemic scleroderma	0.000108	0.000217	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—SMAD7—systemic scleroderma	0.000107	0.000216	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—CTGF—systemic scleroderma	0.000106	0.000214	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—EDN1—systemic scleroderma	0.000105	0.000211	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—MMP1—systemic scleroderma	0.000105	0.000211	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—HSPG2—systemic scleroderma	0.000104	0.000209	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—MMP9—systemic scleroderma	0.000104	0.000209	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR ligand binding—CCL2—systemic scleroderma	0.000103	0.000207	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—EDN1—systemic scleroderma	0.000103	0.000207	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—HSPG2—systemic scleroderma	0.000102	0.000205	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CSK—systemic scleroderma	0.000101	0.000202	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CSK—systemic scleroderma	9.85e-05	0.000198	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—MMP9—systemic scleroderma	9.84e-05	0.000198	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	9.78e-05	0.000197	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR ligand binding—CCL2—systemic scleroderma	9.57e-05	0.000192	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—EDN1—systemic scleroderma	9.55e-05	0.000192	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—HSPG2—systemic scleroderma	9.37e-05	0.000188	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—EDN1—systemic scleroderma	9.35e-05	0.000188	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—RHOB—systemic scleroderma	8.94e-05	0.00018	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—MMP9—systemic scleroderma	8.79e-05	0.000177	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—TGFB1—systemic scleroderma	8.57e-05	0.000172	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—EDN1—systemic scleroderma	8.51e-05	0.000171	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—HSPG2—systemic scleroderma	8.43e-05	0.000169	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—RHOB—systemic scleroderma	8.31e-05	0.000167	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CSK—systemic scleroderma	8.15e-05	0.000164	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—TGFB1—systemic scleroderma	8.11e-05	0.000163	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—EDN1—systemic scleroderma	7.91e-05	0.000159	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—HSPG2—systemic scleroderma	7.84e-05	0.000157	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—EDN1—systemic scleroderma	7.73e-05	0.000155	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—NOS3—systemic scleroderma	7.63e-05	0.000153	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CSK—systemic scleroderma	7.57e-05	0.000152	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—TGFB1—systemic scleroderma	7.25e-05	0.000146	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—EDN1—systemic scleroderma	7.18e-05	0.000144	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—CTGF—systemic scleroderma	7.1e-05	0.000143	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—CCL2—systemic scleroderma	6.53e-05	0.000131	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—CCL2—systemic scleroderma	6.39e-05	0.000128	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—HSPG2—systemic scleroderma	6.11e-05	0.000123	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—EDN1—systemic scleroderma	5.64e-05	0.000113	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—EDN1—systemic scleroderma	5.52e-05	0.000111	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CCL2—systemic scleroderma	5.28e-05	0.000106	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—TGFB1—systemic scleroderma	5.04e-05	0.000101	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CCL2—systemic scleroderma	4.91e-05	9.86e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CTGF—systemic scleroderma	4.63e-05	9.3e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—NOS3—systemic scleroderma	4.63e-05	9.3e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—EDN1—systemic scleroderma	4.57e-05	9.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—EDN1—systemic scleroderma	4.24e-05	8.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CCL2—systemic scleroderma	3.86e-05	7.75e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCL2—systemic scleroderma	3.77e-05	7.58e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—NOS3—systemic scleroderma	3.44e-05	6.91e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—NOS3—systemic scleroderma	3.36e-05	6.76e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCL2—systemic scleroderma	3.12e-05	6.27e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—NOS3—systemic scleroderma	3.09e-05	6.21e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCL2—systemic scleroderma	2.9e-05	5.83e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—NOS3—systemic scleroderma	2.78e-05	5.59e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MMP9—systemic scleroderma	2.76e-05	5.54e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MMP9—systemic scleroderma	2.7e-05	5.42e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—NOS3—systemic scleroderma	2.59e-05	5.19e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—TGFB1—systemic scleroderma	2.27e-05	4.57e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MMP9—systemic scleroderma	2.23e-05	4.48e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—TGFB1—systemic scleroderma	2.22e-05	4.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MMP9—systemic scleroderma	2.07e-05	4.17e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—NOS3—systemic scleroderma	2.01e-05	4.05e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TGFB1—systemic scleroderma	1.84e-05	3.7e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TGFB1—systemic scleroderma	1.71e-05	3.43e-05	CbGpPWpGaD
